Merck (MRK) reported $65.0B in revenue for fiscal 2025, +1.3% year on year. That ranks #76 by revenue among 2853 SEC filers and #13 in Healthcare. Net income was $18.3B, a net margin of 28.1%. Revenue has grown 5.6% a year on average since 2016 ($39.8B then). The fiscal 2025 balance sheet shows $137B in total assets, $14.6B in cash and $46.8B in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenues | $65.0B | +1.3% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest | $21.1B | +5.7% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $18.3B | +6.6% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $16.5B | −23.3% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $4.1B | +21.9% | FY20252025-12-31 |
| Total assetsAssets | $137B | +16.9% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $52.6B | +13.6% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $14.6B | +10.0% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $46.8B | +35.7% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $16.3B | −$4.2B | Open → |
| Q2 20262026-06-30 | $16.6B | −$1.3B | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 16 of 161 companies compared | 28.1% | |
| Operating marginRank 14 of 160 companies compared | 32.4% | |
| R&D as share of revenueRank 19 of 102 companies compared | 24.3% | |
| Cash as share of revenueRank 42 of 160 companies compared | 22.4% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Merck & Co., Inc.
- Ticker
- MRK
- Exchange
- NYSE
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0000310158
Filings
- 10-QAug 7, 2026Open filing →
- 10-QMay 4, 2026Open filing →
- 10-KFeb 24, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Johnson & JohnsonJNJ | $94.2B | $26.8B |
| HCA HealthcareHCA | $75.6B | $6.8B |
| Eli LillyLLY | $65.2B | $20.6B |
| MerckMRK | $65.0B | $18.3B |
| PfizerPFE | $62.6B | $7.8B |
| AbbVieABBV | $61.2B | $4.2B |
| AstraZenecaAZN | $58.7B | $10.2B |
Merck compared withEli LillyPfizer
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Merck — Key figures |url=https://companiesranked.com/en/company/merck |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Merck — Key figures. CompaniesRanked. https://companiesranked.com/en/company/merckBibTeX
@misc{companiesranked-en-company-merck-2026,
author = {{CompaniesRanked}},
title = {{Merck — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/merck}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0000310158-26-000063 · February 24, 2026
{{cite web |title=Merck — Key figures — 10-K (0000310158-26-000063) |url=https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/mrk-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-24}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.